Fliedner University of Applied Sciences Düsseldorf offers a dual study programme "Medical Information Management, B. Sc." starting from winter semester 2021/2022. We offer companies and hospitals the opportunity to enrich their teams with our dual students. The practice-integrating study programme comprises 7 semesters. As a practice partner, you have an impact on which practical experience dual students gain and you are thus directly involved in the competence development of your junior staff. Both learning locations and the knowledge acquired there are mutually coordinated, so that skills and abilities derived from them are integrated independently and comprehensively. The students quickly develop a high level of professional competence.
Details:
https://www.fliedner-fachhochschule.de/medizinisches-informationsmanagement-praxispartner-werden/

Looking for an opportunity as a CRA or in Regulatory affairs in Pharma laboratory or in a CRO

AstraZeneca's Tagrisso (osimertinib) has been recommended for use within NHS England, in line with its licensed indication, for adults with untreated locally-advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
In clinical trials, the drug was shown to provide an overall survival benefit of more than three years when used as a first-line treatment compared to first-generation medicines in the same class.
Clinical data also show that Tagrisso has a more significant impact on cancer that has spread to the central nervous system and a favourable side effect profile, AZ noted.
Lung cancer is currently the most common cause of cancer death in the UK, accounting for one in five (21%) of all cancer deaths.
Read more: http://www.pharmatimes.com/news/nice_backing_for_az_tagrisso_1350193

Read more: https://onlinemedicalwriting.com/blog/2020/08/31/medical-writing-for-patient-education-an-informed-approach-to-health-communications/

US regulators have approved Genentech's Gavreto (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).
The indication was approved under the FDA's accelerated approval programme based on data from the Phase I/II ARROW study, and so continued clearance may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.
According to the firm, in the Phase I/II ARROW study Gavreto produced “durable clinical responses” in people with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.
Read more: http://www.pharmatimes.com/news/genentechs_gavreto_cleared_for_ret_non-small_cell_lung_cancer_1348772

Managed - Branded - Compliant
- Custom Scale to Grow
- Digital & Phone Branded with recording & Opt in information
- Digital Campaign includes Terms, Conditions, Privacy Policy, Opt-out & Agreement info
- NO Brokers or Re-Sellers
Benefits of CGM Campaign include Branding, Exclusive, Compliant and 1 Year Prescriptions
For more information, visit:
https://sites.google.com/view/cgm-managed-campaign/home

Researchers have discovered that an aggressive form of pancreatic cancer 'hijacks' the immune system's response and therefore is more likely to respond to treatment with immunotherapy, raising hopes for new targets in the fight against the disease.
Scientists at The Institute of Cancer Research (ICR), London, and The Royal Marsden NHS Foundation Trust, working with colleagues at the University and Hospital Trust of Verona, Italy, used artificial intelligence (AI) and genetic analysis to study 207 tumour samples from patients with pancreatic neuroendocrine tumours for the levels of 600 immune-related genes.
Comparing four separate forms of the disease, they found that samples of the most aggressive form, known as metastases-like primary tumours, saw changes in activity of 74 immune-related genes, compared with changes in only 12 in the more benign insulinoma-like tumours.
http://www.pharmatimes.com/news/immunotherapies_could_target_aggressive_pancreatic_cancer,_research_indicates_1347800

Eight in ten doctors anticipate a permanent increase in remote interactions with sales representatives. Join this FREE Reuters Events Pharma Webinar https://bit.ly/2DiodiI
with GSK, Pfizer & Ashfield to understand how you can build a roadmap towards a holistic HCP engagement strategy beyond the COVID-19 crisis environment.
*All signups receive the recording – so if you can’t make it on the day, sign up anyway and you’ll get the on-demand version.

Nestlé has announced plans to acquire allergy specialist Aimmune Therapeutics in a deal worth $2.6bn, six months after the biopharmaceutical company’s Palforzia became the first peanut allergy drug to be cleared for use in the US.
Currently, Nestlé has a 25% equity ownership stake in Aimmune, but is set to acquire the outstanding shares in an all-cash offer made through its health division, Nestlé Health Science. The deal is subject to customary closing conditions, although Nestlé expects the transaction to close in the fourth quarter of 2020.
"This transaction brings together Nestlé's nutritional science leadership with one of the most innovative companies in food allergy treatment," said Greg Behar, chief executive officer of Nestlé Health Science.
"Together we will be able to offer a wide range of solutions that can transform the lives of people suffering from food allergies around the world,” he added.
Read more: http://www.pmlive.com/pharma_news/nestle_is_set_to_acquire_aimmune_in_deal_worth_$2.6bn_1347578

It is a grave mistake to neglect developing a relationship with the admin/ assistant of decision makers. As easy as these gatekeepers can get you in, they can just as easily keep you out. #sales #motivation #inspiration #goals #innovation #business #Startup #jobs #sales #money #career #entrepreneurship

As digital health startups develop their sales message & value proposition, they must ensure that both of them resonate with what's important to physicians in order to be successful. #digitalhealth #healthtech #innovation #business #Startup #jobs #pharma #healthcare #sales #technology #entrepreneurship

Digital health startups should ensure that they have the right coaching & strategy to clearly articulate their unique value proposition to the right decision making personas.
#digitalhealth #healthtech #innovation #business #Startup #jobs #pharma #healthcare #sales #technology #entrepreneurship

A sales message should reflect bespoke tailoring of a suit; it should be custom made for each individual persona and customer.
#sales #success #career #salesexcellence #money

Learn more - https://onlinemedicalwriting.com/blog/2020/07/23/interview-for-a-medical-writers-position-what-should-you-know-as-a-fresher/

Last month, The World Health Organization (WHO) held a Digital Health Round Table with Member States. Digital Health startups develop a global strategy, & not just in a local, regional or country viewpoint. Here was one of their key objectives: "Discuss and agree on how to accelerate and adopt digital health solutions including Early warning disease surveillance systems at all levels to jointly accelerate digital transformation of healthcare.”